TEVA director exercises 14,492 RSUs into shares

TEVA PHARMACEUTICAL INDUSTRIES LTD director Tal Zvi Zaks exercised equity awards to receive additional ordinary shares.

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD director Tal Zvi Zaks exercised equity awards to receive additional ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were converted into 14,492 ordinary shares at no cash exercise price, increasing his directly held stake to 73,264 ordinary shares. Each restricted share unit entitled him to one ordinary share, or at the committee’s option, the cash value of one share. The restricted share units were originally granted on June 5, 2025 and fully vested one year later. The ordinary shares may also be held as American Depositary Shares, with each ADS representing one ordinary share.

Insider Trade Summary

14,492 shares exercised/converted

Exercise 2 txns

Insider Zaks Tal Zvi

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	14,492	$0.00	$0.00
Exercise	Ordinary Shares	14,492	$0.00	$0.00

Holdings After Transaction: Restricted Share Units — 0 contracts (Direct); Ordinary Shares — 73,264 shares (Direct)

Footnotes (3)

1. F1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. F2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
3. F3. Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

Key Figures

Shares acquired via RSU exercise: 14,492 shares Post-transaction holdings: 73,264 shares RSU-to-share ratio: 1 unit : 1 share +3 more

6 metrics

Shares acquired via RSU exercise 14,492 shares Restricted share units settled into ordinary shares on June 5, 2026

Post-transaction holdings 73,264 shares Ordinary shares directly held after the June 5, 2026 transaction

RSU-to-share ratio 1 unit : 1 share Each restricted share unit convertible into one ordinary share

ADS to ordinary share ratio 1 ADS : 1 ordinary share Each American Depositary Share currently represents one ordinary share

RSU grant date June 5, 2025 Grant date for the 14,492 restricted share units

RSU vesting date June 5, 2026 Vesting date when RSUs converted into ordinary shares

Key Terms

Restricted share units, American Depositary Shares, derivative exercise/conversion, contingent right, +1 more

5 terms

Restricted share units financial

"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

derivative exercise/conversion financial

"transaction_action: derivative exercise/conversion for the restricted share units"

contingent right financial

"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share"

vested financial

"Restricted share units were granted on June 5, 2025 and vested on June 5, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TEVA director Tal Zvi Zaks report on this Form 4?

Tal Zvi Zaks reported exercising equity awards, converting 14,492 restricted share units into 14,492 ordinary shares. This was a compensation-related derivative exercise rather than an open-market stock purchase or sale, reflecting vesting of previously granted share-based awards.

How many TEVA shares does Tal Zvi Zaks hold after this Form 4 transaction?

After the June 5, 2026 transaction, Tal Zvi Zaks directly holds 73,264 ordinary shares of TEVA. This total reflects the addition of 14,492 shares received from vested restricted share units and shows his updated equity stake following the award settlement.

What exactly happened to the 14,492 restricted share units reported by TEVA?

The 14,492 restricted share units granted on June 5, 2025 vested on June 5, 2026 and were settled into 14,492 ordinary shares. Each unit represented a contingent right to one share or its cash value, at the compensation committee’s discretion.

Did Tal Zvi Zaks buy or sell TEVA shares on the open market in this filing?

This Form 4 does not show any open-market buys or sells by Tal Zvi Zaks. It reports a derivative exercise, where vested restricted share units converted into ordinary shares as part of his equity compensation, with no sale of those shares disclosed.

How are TEVA ordinary shares and American Depositary Shares (ADS) related?

TEVA states that its ordinary shares may be represented by American Depositary Shares. Each ADS currently represents one ordinary share, meaning U.S. investors holding ADSs have an interest equivalent to a single underlying ordinary share per ADS.

When were the TEVA restricted share units granted and when did they vest?

The restricted share units reported in this Form 4 were granted on June 5, 2025 and vested on June 5, 2026. Upon vesting, the 14,492 units were settled into an equal number of ordinary shares as part of Tal Zvi Zaks’ compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zaks Tal Zvi

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV ISRAEL 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/05/2026		M		14,492	A	(2)	73,264	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	06/05/2026		M			14,492	(3)	(3)	Ordinary Shares(1)	14,492	$0	0	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

	/s/ Dov Bergwerk as attorney-in-fact for Tal Zvi Zaks	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)